PharmGen Science Statistics

Total Valuation

PharmGen Science has a market cap or net worth of KRW 86.97 billion. The enterprise value is 89.82 billion.

Market Cap	86.97B
Enterprise Value	89.82B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

PharmGen Science has 18.14 million shares outstanding. The number of shares has decreased by -23.67% in one year.

Current Share Class	n/a
Shares Outstanding	18.14M
Shares Change (YoY)	-23.67%
Shares Change (QoQ)	-4.03%
Owned by Insiders (%)	11.76%
Owned by Institutions (%)	1.21%
Float	15.13M

Valuation Ratios

The trailing PE ratio is 150.61.

PE Ratio	150.61
Forward PE	n/a
PS Ratio	0.48
PB Ratio	0.36
P/TBV Ratio	n/a
P/FCF Ratio	47.23
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.92, with an EV/FCF ratio of 48.78.

EV / Earnings	161.61
EV / Sales	0.52
EV / EBITDA	8.92
EV / EBIT	16.41
EV / FCF	48.78

Financial Position

The company has a current ratio of 1.61, with a Debt / Equity ratio of 0.16.

Current Ratio	1.61
Quick Ratio	1.18
Debt / Equity	0.16
Debt / EBITDA	2.51
Debt / FCF	20.55
Interest Coverage	2.46

Financial Efficiency

Return on equity (ROE) is 0.24% and return on invested capital (ROIC) is 2.39%.

Return on Equity (ROE)	0.24%
Return on Assets (ROA)	1.89%
Return on Capital (ROIC)	2.39%
Revenue Per Employee	697.96M
Profits Per Employee	2.24M
Employee Count	248
Asset Turnover	0.50
Inventory Turnover	2.74

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.86% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.86%
50-Day Moving Average	4,813.70
200-Day Moving Average	5,330.75
Relative Strength Index (RSI)	43.42
Average Volume (20 Days)	35,292

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmGen Science had revenue of KRW 173.09 billion and earned 555.75 million in profits. Earnings per share was 31.84.

Revenue	173.09B
Gross Profit	104.22B
Operating Income	10.49B
Pretax Income	1.77B
Net Income	555.75M
EBITDA	15.08B
EBIT	10.49B
Earnings Per Share (EPS)	31.84

Full Income Statement

Balance Sheet

The company has 34.97 billion in cash and 37.83 billion in debt, giving a net cash position of -2.86 billion or -157.76 per share.

Cash & Cash Equivalents	34.97B
Total Debt	37.83B
Net Cash	-2.86B
Net Cash Per Share	-157.76
Equity (Book Value)	239.59B
Book Value Per Share	13,211.05
Working Capital	38.32B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.81 billion and capital expenditures -969.64 million, giving a free cash flow of 1.84 billion.

Operating Cash Flow	2.81B
Capital Expenditures	-969.64M
Free Cash Flow	1.84B
FCF Per Share	101.52

Full Cash Flow Statement

Margins

Gross margin is 60.21%, with operating and profit margins of 6.06% and 0.32%.

Gross Margin	60.21%
Operating Margin	6.06%
Pretax Margin	1.02%
Profit Margin	0.32%
EBITDA Margin	8.71%
EBIT Margin	6.06%
FCF Margin	1.06%

Dividends & Yields

PharmGen Science does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	23.67%
Shareholder Yield	23.67%
Earnings Yield	0.66%
FCF Yield	2.12%

Stock Splits

The last stock split was on November 17, 2014. It was a reverse split with a ratio of 0.1.

Last Split Date	Nov 17, 2014
Split Type	Reverse
Split Ratio	0.1

Scores

PharmGen Science has an Altman Z-Score of 1.81. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.81
Piotroski F-Score	n/a